MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known 10/784,917 INFORMATION DISCLOSURE **Prior Application Number** STATEMENT BY APPLICANT Prior Appl. Filing Date 02/24/2004 JAN 1 2 7006 **First Named Inventor** Peng Cho TANG Date Submitted: January 12, 2006 1626 Group Art Unit (use as many sheets as necessary) **Examiner Name** Stockton, Laura Attorney Docket Number 034536-1150 Sheet of 3 1

	Same to Second	T-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	/*** / ** <b>2</b> 22. V	a de major de la composición dela composición de la composición de la composición de la composición de la composición dela composición de la composición de la composición dela composición dela composición de la composición de la composición dela composición de la composición de la composición dela composición dela composición dela composición dela composición dela compo	FC	OREIGN PATENT DOCUMEN	TS	and the second of the second o	
Examiner Initials*	Cite No.1	F Office	oreign Patent D	Ocument Kind Co	ode	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
<b>B</b>	C1	AU	286870			IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		
285	C2	CA	2,012,634		A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
H	СЗ	нυ	65452			RICHTER GEDEON BEGYESZETI GYAR RT	06-28-1994	,	
-889	C4	wo	92/03736		A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
sel	C5	wo	94/10202		A1	GENENTECH, INC.	05-11-1994		
SE .	C6	wo	96/32380		A1	PHARMACIA S.P.A.	10-17-1996		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
8	<b>C</b> 7	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990) (Abstract considered by examiner, best available full reference attached)	
$\mathcal{M}$	С8	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones," <u>Eur. J. Med. Chem</u> . 32:919-924 (1997)	
B	C9	Baserga, "Oncogenes and the strategy of growth factors," <u>Cell</u> 79:927-930 (1994)	
20 20 20 20 20 20 20 20 20 20 20 20 20 2	-C10/	Beilstein Reg. No. 233511 (1997)	

_						
			William Total Program in Factor in	er tre se comp manifest au atmostad a pret gal	Management and Company of the	feet a f
Examiner Signature	Kam-	J, S	tole	Date Considered	3/27	106

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>9</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH\_1526797.1

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	form 1449B	/PTO	Complete if Known				
	INFORMATIO	ON DISCLO	SURE	Prior Application Number	10/784,917			
	STATEMENT	BY APPL	CANT	Prior Appl. Filing Date	02/24/2004			
	Data Cubmittos	t: lanuari	2006	First Named Inventor	Peng Cho TANG			
	Date Submitted	i. January	12, 2006	Group Art Unit	1626			
	(use as many si	heets as ne	cessary)	Examiner Name	Stockton, Laura			
Sheet	2	of	3	Attorney Docket Number	034536-1150			

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T®					
<b>A</b>	C11	Borsche et al., "Über nielkernige kondersierte systeme mit heterocyclischen ringen," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)						
A)	C12	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>Chemical Abstracts</u> , Vol. 101, abstract no. 37875 (1984)						
<b>M</b>	C13	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," <u>Chemical Abstracts</u> Vol. 82, abstract no. 72891 (1975)						
<b>A</b>	C14	Houben-Weyl., "Substance Index," Cyclic Compounds V Bicyclic Compounds 1 E23 (834-1018 (1999)						
fb;	C15	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1 <i>H</i> )-benzimidazolone-and oxindole-1 acetic acids" Chemical Abstracts, Vol. 118, abstract no. 254813 (1993)	er even ar even ar even					
<b>A</b>	C16	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," Chemical Abstracts, Vol. 76, abstract no. 21121 (1972)						
Hr.	C17	Schindler et al., "Dibenz[b,f]-azocin-Derivate," Helvetica Chimica Acta 49:985-989 (1966)						
88	C18	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," Collection Czecholslov. Chem. Commun. 42:2201-2206 (1976)						

Contract of the Contract of th		THE RESERVE AND ADDRESS OF THE PARTY OF THE	torres addition tiers in particularly did	Sauther as the the sent. The first desire of the desire the second production of the second	ami sta 100 jii 75 ayaa		
Examiner Signature	X	an P.St	EAS.	Date Considered	3/2	7/06	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH\_1526797.1

. . . . . . .

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in donformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	form 1449B/	PTO	С	Complete if Known				
	INFORMATIO	ON DISCLO	SURE	Prior Application Number	10/784,917				
]	STATEMENT	BY APPLI	CANT	Prior Appl. Filing Date	02/24/2004				
	Date Submitted	ti lanuani 1	2 2006	First Named Inventor	Peng Cho TANG				
	Date Submitted	a. January i	2, 2006	Group Art Unit	1626				
	(use as many si	heets as ne	cessary)	Examiner Name	Stockton, Laura				
Sheet	3	of	3	Attorney Docket Number	034536-1150				

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>⊤</b> 8
	NOT Legible	C19	Sumpter and Miller, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole</u> <u>Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
Can	n/a	<del>-620</del> -	von Dobeneck et al., "α.β'-Diindolykmethane und-methene. Der Urorosein-Chromopher." <u>Zur Chemie des Indols</u> VI:1347-1357 (1969)	
	Æ	C21	Wahl, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)	
	<b>&amp;</b>	C22	Wahl, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909) (see C21, partial duplicate)	
		C23	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>ArzneimForsch./Drug Res.</u> 27(II):2251-2263 (1977)	ر د د د
	<b>8</b> 8	C24	Wright, Beilstein Reg. No. 235900, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956)	
	<b>88</b> 7	C25	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry, Academy of Science of the Moldavian SSR</u> , Kishinev pp. 34-37 translated from <u>Khimiya Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973) (Abstract considered by examiner, full document enclosed, not in English)	

			to the property of the same and description of the same of the sam	Tarabas series as a company of the c		Service and an experience of the service of the ser
Exa Sig	miner nature	X	an L. Stoll	Date Considered	3	27/06
	EVALUNE	Or faither if so	forman annuldered whether are not effective to to accomp			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH\_1526797.1

. ....

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. 
<sup>6</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.